Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
QGEN or RGEN: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 02'nd May 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to v
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
10:10am, Wednesday, 30'th Apr 2025
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript
12:58pm, Tuesday, 29'th Apr 2025
Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland -
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
09:45am, Tuesday, 29'th Apr 2025
Repligen (RGEN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.28 per share a year ago.
Repligen Reports First Quarter 2025 Financial Results
07:30am, Tuesday, 29'th Apr 2025
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Wednesday, 23'rd Apr 2025
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Tuesday, 22'nd Apr 2025
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GMAB or RGEN: Which Is the Better Value Stock Right Now?
12:46pm, Wednesday, 16'th Apr 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value
Repligen Appoints Jacob Johnson As Vice President Investor Relations
07:30am, Tuesday, 08'th Apr 2025
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
05:15am, Tuesday, 08'th Apr 2025
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Repligen: Ongoing Bioprocessing Market Recovery
07:52am, Thursday, 20'th Mar 2025
I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in no
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
01:26pm, Tuesday, 04'th Mar 2025
On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
07:30am, Tuesday, 04'th Mar 2025
Portfolio includes PAT devices for real-time process monitoring, control and analysis Portfolio includes PAT devices for real-time process monitoring, control and analysis
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
11:35am, Friday, 21'st Feb 2025
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript
02:53pm, Thursday, 20'th Feb 2025
Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President an
